Co-architects of the modern understanding of the liver, the chemists who taught it to carry insulin, and the operators bringing it to patients.

Nick has a background in translational biomedical research and nanomaterials development. He is an Associate Professor in the School of Medical Science at the University of Sydney and a laboratory head at the ANZAC Research Institute, where his group focuses on nanotechnologies for clinical application — drug, biologic, and gene therapy delivery.

Nick is Co-Founder and CEO of Endo Axiom, leading the translation of the platform toward clinical trials. He is the lead author on the Nature Nanotechnology 2024 paper that demonstrated enzyme-responsive oral insulin in multiple species, and on the ACS Nano 2020 and 2021 papers that established the underlying silver-sulfide quantum-dot delivery chassis. His research has been supported by the NHMRC, MRFF, MTP Connect, the Australian Diabetes Society, Haemophilia Foundation Australia, the Research Council of Norway, and the University of Sydney.

Gerontologist and clinical pharmacologist at Concord Hospital and the University of Sydney, and co-architect, with Cogger, of the modern understanding of the liver sinusoidal endothelium — the fenestrated “liver sieve”. Officer of the Order of Australia. Three decades of foundational liver pharmacology underpins the company.

Executive Director of the Sydney Biomedical Accelerator and a foundational figure in the study of liver sinusoidal endothelial cells. Cogger’s work characterising the 50-to-150-nanometre fenestrations of the liver sieve — and the consequences of their age-related closure — directly informed the size and surface chemistry of the Endo Axiom delivery particle.

Chairman of Endo Axiom and Chief Investment Officer of Scientia Capital, a specialised global investment fund focused exclusively on life sciences.

Prior to Scientia, Lawrence was responsible for the largest biotechnology investment portfolio in Australia as the institutional biotechnology analyst at Queensland Investment Corporation, an investment fund managing over A$60 billion.

Anthony Liveris is a Director of Endo Axiom and the Chief Executive Officer of Proto Axiom, the Australian company-creator backing Endo as the first of four CSL-scale therapeutics businesses Proto intends to build over twenty years.

Prior to Proto Axiom, Anthony co-founded Applecart, the New York data and technology company that attracted a US$100 million investment from Blackstone Growth. He has also held roles with former Australian Prime Minister Malcolm Turnbull, the Tony Blair Institute, and on the U.S. presidential campaigns of Mitt Romney and John Kasich.

Anthony serves as Chairman of the St. Vincent’s Hospital Discovery and Innovation Fund. He holds a Master of Public Policy from the Blavatnik School of Government at the University of Oxford and a Bachelor of Arts from the University of Pennsylvania.

Samantha has more than 20 years in clinical trial management, including phase 1 studies at Johnson & Johnson. She leads Endo Axiom’s clinical trial operations and management with our CRO partners, Data Pharma and CMAX Clinical Research, and has led large clinical trial programmes and teams running multiple trials.

Scientific advisor to Endo Axiom and Chief Science Officer of Proto Axiom. Lindsay is an NHMRC Research Fellow and Head of the Laboratory for Ageing Research at UNSW Sydney, with a background in molecular biology, biochemistry, and drug development.

He has held Scientific Advisor and Chief Scientific Advisor roles at Life Biosciences, Metro Biotech, JumpStart Fertility, and Intravital. Lindsay received his PhD at the Garvan Institute of Medical Research after studying at the University of Sydney.